Cite
Sheridan J, Coe CA, Doran P, et al. Protocol for a multicentred randomised controlled trial investigating the use of personalised golimumab dosing tailored to inflammatory load in ulcerative colitis: the GOAL-ARC study (GLM dose Optimisation to Adequate Levels to Achieve Response in Colitis) led by the INITIAtive group (NCT 0268772). BMJ Open Gastroenterol. 2018;5(1):e000174doi: 10.1136/bmjgast-2017-000174.
Sheridan, J., Coe, C. A., Doran, P., Egan, L., Cullen, G., Kevans, D., Leyden, J., Galligan, M., O'Toole, A., McCarthy, J., & Doherty, G. (2018). Protocol for a multicentred randomised controlled trial investigating the use of personalised golimumab dosing tailored to inflammatory load in ulcerative colitis: the GOAL-ARC study (GLM dose Optimisation to Adequate Levels to Achieve Response in Colitis) led by the INITIAtive group (NCT 0268772). BMJ open gastroenterology, 5(1), e000174. https://doi.org/10.1136/bmjgast-2017-000174
Sheridan, Juliette, et al. "Protocol for a multicentred randomised controlled trial investigating the use of personalised golimumab dosing tailored to inflammatory load in ulcerative colitis: the GOAL-ARC study (GLM dose Optimisation to Adequate Levels to Achieve Response in Colitis) led by the INITIAtive group (NCT 0268772)." BMJ open gastroenterology vol. 5,1 (2018): e000174. doi: https://doi.org/10.1136/bmjgast-2017-000174
Sheridan J, Coe CA, Doran P, Egan L, Cullen G, Kevans D, Leyden J, Galligan M, O'Toole A, McCarthy J, Doherty G. Protocol for a multicentred randomised controlled trial investigating the use of personalised golimumab dosing tailored to inflammatory load in ulcerative colitis: the GOAL-ARC study (GLM dose Optimisation to Adequate Levels to Achieve Response in Colitis) led by the INITIAtive group (NCT 0268772). BMJ Open Gastroenterol. 2018 Jan 11;5(1):e000174. doi: 10.1136/bmjgast-2017-000174. eCollection 2018. PMID: 29379609; PMCID: PMC5783109.
Copy
Download .nbib